Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.…
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (NASDAQ: ENTA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 7.620 USD on 20 November 2026, down 30.7% over 52 weeks. Its 52-week range is 7.560 USD to 17.15 USD, and it trades at the bottom of that range.
Its market capitalisation is 222.19M USD.
Enanta Pharmaceuticals reports return on equity of -126.5%, an operating margin of -99.0% and revenue down 14.9% year over year.
It holds more cash than debt, a net cash position of 16.86M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.50 USD is 182.2% above the current price. The next earnings report is expected on 8 February 2027.